The Spectrum of NAFLD: From the Organ to the System

  • Yolanda Sanchez-Torrijos
  • Javier AmpueroEmail author


Non-alcoholic fatty liver disease (NAFLD) is a clinical-pathological condition that encompasses a wide range of liver damage not caused by chronic alcohol consumption, including steatosis, non-alcoholic steatohepatitis (NASH) and cirrhosis, in the absence of other etiologies. It is associated with metabolic risk factors such as obesity, dyslipidemia, and diabetes mellitus. The prevalence of NAFLD has increased considerably over the last years due to the current lifestyle (unhealthy diet and sedentarism). Despite NAFLD is considered the hepatic manifestation of the metabolic syndrome, there is an increasing number of studies that support a bidirectional model, in which NAFLD plays a crucial role in the development of metabolic disturbances. Also, there is strong evidence that supports the multisystemic affectation of NAFLD, including cardiovascular, bone and kidney disease, and promoting hepatic and extrahepatic malignancies.


  1. 1.
    Liu W, Baker RD, Bhatia T, Zhu L, Baker SS. Pathogenesis of nonalcoholic steatohepatitis. Cell Mol Life Sci. 2016;73(10):1969–87.PubMedCrossRefGoogle Scholar
  2. 2.
    Higuera-de la Tijera F, Servín-Caamaño AI. Pathophysiological mechanisms involved in non-alcoholic steatohepatitis and novel potential therapeutic targets. World J Hepatol. 2015;7(10):1297–301.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Ampuero J, Aller R, Gallego-Durán R, Banales JM, Crespo J, García-Monzón C, et al. The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. Aliment Pharmacol Ther. 2018;48(11–12):1260–70.PubMedCrossRefGoogle Scholar
  4. 4.
    Barrera F, George J. The role of diet and nutritional intervention for the management of patients with NAFLD. Clin Liver Dis. 2014;18(1):91–112.PubMedCrossRefGoogle Scholar
  5. 5.
    Gerber L, Otgonsuren M, Mishra A, Escheik C, Birerdinc A, Stepanova M, et al. Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population-based study. Aliment Pharmacol Ther. 2012;36(8):772–81.PubMedCrossRefGoogle Scholar
  6. 6.
    Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142(7):1592–609.PubMedCrossRefGoogle Scholar
  7. 7.
    McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015;62(5):1148–55.PubMedCrossRefGoogle Scholar
  8. 8.
    Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66(6):1138–53.PubMedCrossRefGoogle Scholar
  9. 9.
    Li AA, Ahmed A, Kim D. Extrahepatic manifestations of nonalcoholic fatty liver disease. Gut Liver. 2019;15(2):75–85.Google Scholar
  10. 10.
    Wong VW-S, Adams LA, de Lédinghen V, Wong GL-H, Sookoian S. Noninvasive biomarkers in NAFLD and NASH—current progress and future promise. Nat Rev Gastroenterol Hepatol. 2018;15(8):461–78.PubMedCrossRefGoogle Scholar
  11. 11.
    Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–57.PubMedCrossRefGoogle Scholar
  12. 12.
    Wong VW-S, Chan W-K, Chitturi S, Chawla Y, Dan YY, Duseja A, et al. Asia-pacific working party on non-alcoholic fatty liver disease guidelines 2017-Part 1: definition, risk factors and assessment. J Gastroenterol Hepatol. 2018;33(1):70–85.PubMedCrossRefGoogle Scholar
  13. 13.
    Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547–54.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148(3):547–55.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Sanchez-Torrijos Y, Ampuero J, Romero-Gómez M. Cardiovascular assessment in liver transplant for non-alcoholic steatohepatitis patients: what we do, what we should do. World J Hepatol. 2017;9(15):697.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Ampuero J, Gallego-Durán R, Romero-Gómez M. Association of NAFLD with subclinical atherosclerosis and coronary-artery disease: meta-analysis. Rev Esp Enferm Dig. 2015;107(1):10–6.PubMedGoogle Scholar
  17. 17.
    VanWagner LB, Wilcox JE, Colangelo LA, Lloyd-Jones DM, Carr JJ, Lima JA, et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: a population-based study. Hepatology. 2015;62(3):773–83.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Fracanzani AL, Tiraboschi S, Pisano G, Consonni D, Baragetti A, Bertelli C, et al. Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10 years of follow-up. Atherosclerosis. 2016;246:208–13.PubMedCrossRefGoogle Scholar
  19. 19.
    Wu S, Wu F, Ding Y, Hou J, Bi J, Zhang Z. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis. Sci Rep. 2016;6(1):33386.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL–EASD–EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–402.CrossRefGoogle Scholar
  21. 21.
    Marcuccilli M, Chonchol M. NAFLD and chronic kidney disease. Int J Mol Sci. 2016;17(4):1–15.CrossRefGoogle Scholar
  22. 22.
    Musso G, Cassader M, Cohney S, Pinach S, Saba F, Gambino R. Emerging liver-kidney interactions in nonalcoholic fatty liver disease. Trends Mol Med. 2015;21(10):645–62.PubMedCrossRefGoogle Scholar
  23. 23.
    Targher G, Bertolini L, Rodella S, Lippi G, Zoppini G, Chonchol M. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol. 2010;5(12):2166–71.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Musso G, Gambino R, Tabibian JH, Ekstedt M, Kechagias S, Hamaguchi M, et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med. 2014;11(7):e1001680.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    VanWagner LB, Rinella ME. Extrahepatic manifestations of nonalcoholic fatty liver disease. Curr Hepatol Rep. 2016;15(2):75–85.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Yu J, Shen J, Sun TT, Zhang X, Wong N. Obesity, insulin resistance, NASH and hepatocellular carcinoma. Semin Cancer Biol. 2013;23(6 Pt B):483–91.PubMedCrossRefGoogle Scholar
  27. 27.
    Larsson SC, Wolk A. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer. 2007;97(7):1005–8.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Wainwright P, Scorletti E, Byrne CD. Type 2 diabetes and hepatocellular carcinoma: risk factors and pathogenesis. Curr Diab Rep. 2017;17(4):20.PubMedCrossRefGoogle Scholar
  29. 29.
    Hassan MM, Abdel-Wahab R, Kaseb A, Shalaby A, Phan AT, El-Serag HB, et al. Obesity early in adulthood increases risk but does not affect outcomes of hepatocellular carcinoma. Gastroenterology. 2015;149(1):119–29.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Adami HO, Chow WH, Nyrén O, Berne C, Linet MS, Ekbom A, et al. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst. 1996;88(20):1472–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Lai M-S, Hsieh M-S, Chiu Y-H, Chen TH-H. Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis virus infection. Hepatology. 2006;43(6):1295–302.PubMedCrossRefGoogle Scholar
  32. 32.
    Tanaka K, Tsuji I, Tamakoshi A, Matsuo K, Wakai K, Nagata C, et al. Diabetes mellitus and liver cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. Jpn J Clin Oncol. 2014;44(10):986–99.PubMedCrossRefGoogle Scholar
  33. 33.
    Younossi ZM, Otgonsuren M, Henry L, Venkatesan C, Mishra A, Erario M, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology. 2015;62(6):1723–30.CrossRefGoogle Scholar
  34. 34.
    Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology. 2014;59(6):2188–95.PubMedCrossRefGoogle Scholar
  35. 35.
    Mittal S, El-Serag HB, Sada YH, Kanwal F, Duan Z, Temple S, et al. Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2016;14(1):124–131.e1.PubMedCrossRefGoogle Scholar
  36. 36.
    Piscaglia F, Svegliati-Baroni G, Barchetti A, Pecorelli A, Marinelli S, Tiribelli C, et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study. Hepatology. 2016;63(3):827–38.PubMedCrossRefGoogle Scholar
  37. 37.
    Aller R, Fernández-Rodríguez C, lo Iacono O, Bañares R, Abad J, Carrión JA, et al. Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). Guía de práctica clínica. Gastroenterol Hepatol. 2018;41(5):328–49.PubMedCrossRefGoogle Scholar
  38. 38.
    Bergström A, Pisani P, Tenet V, Wolk A, Adami HO. Overweight as an avoidable cause of cancer in Europe. Int J Cancer. 2001;91(3):421–30.PubMedCrossRefGoogle Scholar
  39. 39.
    Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625–38.PubMedCrossRefGoogle Scholar
  40. 40.
    Kim G-A, Lee HC, Choe J, Kim M-J, Lee MJ, Chang H-S, et al. Association between non-alcoholic fatty liver disease and cancer incidence rate. J Hepatol. 2018;68(1):140–6.CrossRefGoogle Scholar
  41. 41.
    Parizadeh SM, Parizadeh SA, Alizade-Noghani M, Jafarzadeh-Esfehani R, Ghandehari M, Mottaghi-Moghaddam A, et al. Association between non-alcoholic fatty liver disease and colorectal cancer. Expert Rev Gastroenterol Hepatol. 2019;13(7):633–41. Scholar
  42. 42.
    Lee YI, Lim Y-S, Park HS. Colorectal neoplasms in relation to non-alcoholic fatty liver disease in Korean women: a retrospective cohort study. J Gastroenterol Hepatol. 2012;27(1):91–5.PubMedCrossRefGoogle Scholar
  43. 43.
    Ahn JS, Sinn DH, Min YW, Hong SN, Kim HS, Jung S-H, et al. Non-alcoholic fatty liver diseases and risk of colorectal neoplasia. Aliment Pharmacol Ther. 2017;45(2):345–53.PubMedCrossRefGoogle Scholar
  44. 44.
    Kurra S, Fink DA, Siris ES. Osteoporosis-associated fracture and diabetes. Endocrinol Metab Clin N Am. 2014;43(1):233–43.CrossRefGoogle Scholar
  45. 45.
    Armstrong MJ, Adams LA, Canbay A, Syn W-K. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology. 2014;59(3):1174–97.PubMedCrossRefGoogle Scholar
  46. 46.
    Chen H-J, Yang H-Y, Hsueh K-C, Shen C-C, Chen R-Y, Yu H-C, et al. Increased risk of osteoporosis in patients with nonalcoholic fatty liver disease. Medicine (Baltimore). 2018;97(42):e12835.CrossRefGoogle Scholar
  47. 47.
    Moon S-S, Lee Y-S, Kim SW. Association of nonalcoholic fatty liver disease with low bone mass in postmenopausal women. Endocrine. 2012;42(2):423–9.PubMedCrossRefGoogle Scholar
  48. 48.
    Sun Y, Dai W, Liang Y, Yang P, Yang Q, Liang M, et al. Relationship between nonalcoholic fatty liver disease and bone mineral density in adolescents with obesity: a meta-analysis. Diabetes Metab Syndr Obes Targets Ther. 2019;12:199–207.CrossRefGoogle Scholar
  49. 49.
    Upala S, Jaruvongvanich V, Wijarnpreecha K, Sanguankeo A. Nonalcoholic fatty liver disease and osteoporosis: a systematic review and meta-analysis. J Bone Miner Metab. 2017;35(6):685–93.PubMedCrossRefGoogle Scholar
  50. 50.
    Kotronen A, Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28(1):27–38.PubMedCrossRefGoogle Scholar
  51. 51.
    Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig Liver Dis. 2015;47(3):181–90.PubMedCrossRefGoogle Scholar
  52. 52.
    Park SK, Seo MH, Shin HC, Ryoo J-H. Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study. Hepatology. 2013;57(4):1378–83.PubMedCrossRefGoogle Scholar
  53. 53.
    Yamazaki H, Tsuboya T, Tsuji K, Dohke M, Maguchi H. Independent association between improvement of nonalcoholic fatty liver disease and reduced incidence of type 2 diabetes. Diabetes Care. 2015;38(9):1673–9.PubMedCrossRefGoogle Scholar
  54. 54.
    Björkström K, Stål P, Hultcrantz R, Hagström H. Histologic scores for fat and fibrosis associate with development of type 2 diabetes in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2017;15(9):1461–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Unidad de Aparato DigestivoHospital Universitario Virgen del RocioSevillaSpain
  2. 2.Instituto de Biomedicina de SevillaSevillaSpain
  3. 3.Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd)MadridSpain
  4. 4.Universidad de SevillaSevillaSpain

Personalised recommendations